Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

This study is comparing two different chemotherapy regimens — venetoclax + azacitidine (VA) versus decitabine + idarubicin + cytarabine (D/IA) — as initial treatments for older adults with acute myeloid leukemia (AML), a fast-moving blood cancer. **You may be eligible if...** - You are 55–75 years old - You have been newly diagnosed with AML according to current medical guidelines - You are in reasonably good functional health (able to do some daily activities) - Your heart, liver, and kidneys are functioning well enough for treatment **You may NOT be eligible if...** - You have a specific subtype of AML called acute promyelocytic leukemia (APL) or AML with certain genetic markers (RUNX1-RUNX1T1, CBFB-MYH11, or BCR-ABL) - Your AML has come back after previous induction chemotherapy - You have other conditions that would make these chemotherapy drugs unsafe Talk to your doctor to see if this trial is right for you.